Highlights

  • Revenue rose 12.7% to A$10.867 billion and underlying EBITDA increased 10.6% to A$1.933 billion.
  • Sonic guides to constant-currency FY27 EBITDA of A$1.95 billion to A$2.03 billion, excluding roughly A$30 million of back-office IT transformation costs.
  • The FY26 final Dividend was 63 cents per share, taking the full-year payment to A$1.08.
  • The delayed UK contract recovery, reimbursement changes and currency fluctuations all complicate the guidance.

Sonic Healthcare (ASX:SHL) has become a bigger diagnostics business, but bigger does not automatically mean faster Earnings growth. Acquisitions helped lift FY26 Revenue and profit, while the FY27 outlook points to only modest EBITDA expansion. That shifts the Investment case toward integration, efficiency and the ability to absorb regulatory fee cuts across its international pathology network.

A Stronger FY26 Base

Revenue rose 12.7% to A$10.867 billion and underlying EBITDA increased 10.6% to A$1.933 billion. Statutory net profit after tax reached A$608 million, while Underlying Profit was A$621 million. Pathology remained the largest contributor, with radiology adding diversification. Acquisitions in Germany and the United States helped expand the group, but they also raised the importance of execution and funding discipline.

The FY27 Range Is More Restrained

Sonic guides to constant-currency FY27 EBITDA of A$1.95 billion to A$2.03 billion, excluding roughly A$30 million of back-office IT transformation costs. The company expects organic revenue growth near 5%. A US operating review could contribute A$25 million to A$30 million, but Swiss regulatory fee reductions are expected to reduce revenue by about A$40 million. The balance of these forces will shape Margin progression.

Dividends Hold as Debt Remains Material

The FY26 final dividend was 63 cents per share, taking the full-year payment to A$1.08. Net debt was A$3.069 billion at June, with gearing of 25.9%. Debt and Interest Cover remained within covenant limits, although interest costs are expected to rise. The company has financial headroom, but that does not remove the need to convert Acquisition benefits into cash.

The Wider Sector Test

Healthcare investors must separate clinical or service Demand from the costs of delivering it. Regulation, reimbursement and operating capacity can alter margins even when revenue rises. The most durable growth is supported by repeatable delivery, clear cash conversion and manageable funding needs. That makes execution milestones at least as important as a promising headline result.

Integration Is the Main Risk

The delayed UK contract recovery, reimbursement changes and currency fluctuations all complicate the guidance. Acquired laboratories must deliver planned efficiencies without weakening service quality. Investors should watch the half-year update for evidence that operating improvements are arriving on time. The next results update should be judged against the company’s stated operating targets, balance-sheet capacity and the timing of any promised benefits. Those indicators can reveal deterioration before it appears in full-year earnings.

The Next Evidence to Watch

Sonic operates across several reimbursement systems, which spreads geographic exposure but also multiplies regulatory complexity. Pathology dominates revenue, while radiology and medical services provide additional earnings streams. The LADR acquisition in Germany and US expansion increase the opportunity for scale efficiencies, yet integration benefits can arrive unevenly. In the United Kingdom, recovery on a delayed contract is not expected until later than the FY27 period, limiting one near-term lever. Management must therefore extract improvements elsewhere without assuming that every region will contribute at the same pace. Constant-currency guidance should also be distinguished from reported Australian-dollar results.